JUST-EVOTEC BIOLOGICS EU : revenue, balance sheet and financial ratios

JUST-EVOTEC BIOLOGICS EU is a French company founded 5 years ago, specialized in the sector Fabrication de produits pharmaceutiques de base. Based in TOULOUSE (31100), this company of category ETI shows in 2024 a revenue of 5.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - JUST-EVOTEC BIOLOGICS EU (SIREN 894420603)
Indicator 2024 2023 2022 2021
Revenue 5 733 004 € 211 846 € 1 667 € N/C
Net income -16 666 308 € -5 634 018 € -1 775 056 € -725 924 €
EBITDA -15 773 144 € -5 532 668 € -1 618 128 € -700 908 €
Net margin -290.7% -2659.5% -106482.1% N/C

Revenue and income statement

In 2024, JUST-EVOTEC BIOLOGICS EU achieves revenue of 5.7 M€. Over the period 2022-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +5764.4%. Vs 2023, growth of +2606% (212 k€ -> 5.7 M€). After deducting consumption (369 €), gross margin stands at 5.7 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -15.8 M€, representing -275.1% of revenue. Positive scissor effect: EBITDA margin improves by +2336.5 pts, sign of improved operational efficiency. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -16.7 M€ (-290.7% of revenue), which will impact equity.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

5 733 004 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

5 732 635 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-15 773 144 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-17 121 544 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

-16 666 308 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

-275.1%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 16%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 78%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

15.92%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

77.906%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

-277.214%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

-1.825

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

99.6%

Solvency indicators evolution
JUST-EVOTEC BIOLOGICS EU

Sector positioning

Debt ratio
15.92 2024
2022
2023
2024
Q1: 0.0
Med: 3.24
Q3: 65.34
Average

In 2024, the debt ratio of JUST-EVOTEC BIOLOGICS EU (15.92) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
77.91% 2024
2022
2023
2024
Q1: 17.24%
Med: 45.12%
Q3: 75.14%
Excellent +8 pts over 3 years

In 2024, the financial autonomy of JUST-EVOTEC BIOLOGICS EU (77.9%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
-1.82 years 2024
2022
2023
2024
Q1: -1.5 years
Med: 0.0 years
Q3: 1.31 years
Excellent

In 2024, the repayment capacity of JUST-EVOTEC BIOLOGICS EU (-1.82) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 42.42. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

42.422

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-6.566

Liquidity indicators evolution
JUST-EVOTEC BIOLOGICS EU

Sector positioning

Liquidity ratio
42.42 2024
2022
2023
2024
Q1: 92.26
Med: 208.82
Q3: 371.21
Watch -19 pts over 3 years

In 2024, the liquidity ratio of JUST-EVOTEC BIOLOGICS EU (42.42) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Interest coverage
-6.57x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.82x
Q3: 13.45x
Watch

In 2024, the interest coverage of JUST-EVOTEC BIOLOGICS EU (-6.6x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 82 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 416 days. Excellent situation: suppliers finance 334 days of the operating cycle (retail model). Inventory turnover is 64 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 351 days of revenue, i.e. 5.6 M€ to permanently finance.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

5 585 264 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

82 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

416 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

64 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

351 j

WCR and payment terms evolution
JUST-EVOTEC BIOLOGICS EU

Positioning of JUST-EVOTEC BIOLOGICS EU in its sector

Comparison with sector Fabrication de produits pharmaceutiques de base

Similar companies (Fabrication de produits pharmaceutiques de base)

Compare JUST-EVOTEC BIOLOGICS EU with other companies in the same sector:

Voir toutes les statistiques du secteur Fabrication de produits pharmaceutiques de base

Frequently asked questions about JUST-EVOTEC BIOLOGICS EU

What is the revenue of JUST-EVOTEC BIOLOGICS EU ?

The revenue of JUST-EVOTEC BIOLOGICS EU in 2024 is 5.7 M€.

Is JUST-EVOTEC BIOLOGICS EU profitable?

JUST-EVOTEC BIOLOGICS EU recorded a net loss in 2024.

Where is the headquarters of JUST-EVOTEC BIOLOGICS EU ?

The headquarters of JUST-EVOTEC BIOLOGICS EU is located in TOULOUSE (31100), in the department Haute-Garonne.

Where to find the tax return of JUST-EVOTEC BIOLOGICS EU ?

The tax return of JUST-EVOTEC BIOLOGICS EU is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does JUST-EVOTEC BIOLOGICS EU operate?

JUST-EVOTEC BIOLOGICS EU operates in the sector Fabrication de produits pharmaceutiques de base (NAF code 21.10Z). See the 'Sector positioning' section above to compare the company with its competitors.